Endo International (ENDP) Coverage Initiated by Analysts at SunTrust Banks

SunTrust Banks began coverage on shares of Endo International (NASDAQ:ENDP) (TSE:ENL) in a note issued to investors on Tuesday, MarketBeat Ratings reports. The firm set a “buy” rating and a $13.00 price target on the stock. SunTrust Banks’ price objective suggests a potential upside of 48.06% from the company’s current price.

A number of other analysts have also recently commented on ENDP. Zacks Investment Research cut Endo International from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 14th. ValuEngine upgraded Endo International from a “sell” rating to a “hold” rating in a research report on Tuesday, March 12th. JPMorgan Chase & Co. reduced their price target on Endo International from $16.00 to $10.00 and set a “neutral” rating for the company in a research report on Monday. BidaskClub cut Endo International from a “buy” rating to a “hold” rating in a research report on Wednesday, March 6th. Finally, Canaccord Genuity set a $17.00 price target on Endo International and gave the stock a “buy” rating in a research report on Friday, March 8th. Fifteen investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Endo International has a consensus rating of “Hold” and an average target price of $15.17.

Endo International stock traded up $0.01 during mid-day trading on Tuesday, reaching $8.78. 21,832 shares of the stock traded hands, compared to its average volume of 4,381,593. The stock has a market cap of $1.93 billion, a PE ratio of 3.04 and a beta of 1.21. Endo International has a 12-month low of $5.27 and a 12-month high of $18.50.

Endo International (NASDAQ:ENDP) (TSE:ENL) last posted its quarterly earnings data on Thursday, February 28th. The company reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.59 by $0.16. Endo International had a negative return on equity of 337.13% and a negative net margin of 35.00%. During the same quarter in the previous year, the firm earned $0.77 earnings per share. Equities research analysts anticipate that Endo International will post 2.17 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. LS Investment Advisors LLC bought a new position in Endo International during the fourth quarter valued at approximately $59,000. Oregon Public Employees Retirement Fund bought a new position in Endo International during the fourth quarter valued at approximately $76,000. First Quadrant L P CA bought a new position in Endo International during the fourth quarter valued at approximately $92,000. Neuburgh Advisers LLC boosted its stake in Endo International by 13.9% during the fourth quarter. Neuburgh Advisers LLC now owns 24,860 shares of the company’s stock valued at $181,000 after buying an additional 3,036 shares during the last quarter. Finally, Neuberger Berman Group LLC bought a new position in Endo International during the third quarter valued at approximately $202,000. 92.40% of the stock is owned by hedge funds and other institutional investors.

About Endo International

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.

See Also: Hedge Funds – How They Work For Investors

Analyst Recommendations for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit